Desmopressin Acetate Injection

The core value of desmopressin acetate injection in the regulation system of bleeding and coagulation function in the body is reflected in its precise targeting of coagulation related regulatory pathways, targeted upregulation of plasma concentrations of two key coagulation related substances, coagulation factor VIII (FVIII) and von Willebrand factor (vWF), in the blood, breaking the weak hemostatic function caused by insufficient quantification of coagulation substances. At the same time, its effect has high disease adaptability, which can meet the long-term intervention and acute bleeding control needs of specific bleeding disorders, as well as the preoperative bleeding preventive regulation in specific surgical scenarios, providing diversified and precise support for clinical bleeding management. Specific analysis can be carried out from the following three core dimensions:

This substance specifically binds to the V2 receptor on the surface of vascular endothelial cells, triggering a signal transduction process mediated by cyclic adenosine monophosphate, and promoting the exocytosis of Weibull Pallad bodies storing coagulation factor VIII (FVIII) and von Willebrand factor (vWF) in endothelial cells, achieving rapid release of both substances and upregulation of plasma levels. Compared to the baseline state, it can increase the level of vWF in plasma to 2-4 times the original level, and FVIII activity can also be increased to varying degrees, thereby compensating for the insufficient quantification of related coagulation substances in the body, strengthening the initiation and promotion of coagulation cascade reactions, and providing necessary material basis for the hemostasis process. Moreover, this upregulation effect is dose-dependent and can achieve precise regulation of efficacy within a reasonable dosage range.

This substance has clear compatibility with mild hemophilia A, and the FVIII coagulation activity in such patients is usually higher than 5%. There are no FVIII antibodies present, and after administration, FVIII levels can be upregulated to effectively control spontaneous bleeding or post-traumatic bleeding, such as joint bleeding, muscle hematoma, etc., reducing the frequency and severity of bleeding without relying on exogenous coagulation factor replacement therapy. In the intervention of hemophilia, it is mainly suitable for type 1 and some type 2a patients, who often have quantitative defects in vWF. After administration, it can increase vWF levels, enhance platelet adhesion to vascular endothelium, and improve bleeding tendency. It is particularly suitable for daily bleeding prevention and control in mild to moderate patients, but has no significant effect on patients with qualitative abnormalities or severe deficiency of vWF.

In specific surgical scenarios, this substance can serve as an auxiliary measure for preoperative bleeding prevention and control, especially suitable for patients with mild coagulation dysfunction who do not require strong coagulation intervention, such as dental surgery, small orthopedic surgery, etc. Preoperative standardized administration can increase FVIII and vWF levels in the body in a short period of time, shorten the activated partial thromboplastin time, reduce bleeding during surgery, and lower the need for intraoperative blood transfusion. Its duration of action can cover the entire surgical process and early postoperative period, providing a guarantee for surgical safety and avoiding the risk of excessive coagulation that may be caused by potent hemostatic drugs.

The pressure boosting effect caused by molecular structure modification is weakened.

Natural vasopressin, as an endogenous hormone, contains fragments in its molecular structure that can specifically bind to vascular smooth muscle V1a receptors. After binding, it triggers vasoconstriction, leading to an increase in blood pressure. This effect is more pronounced at higher doses and may increase the burden on the cardiovascular system. Acetic acid deamination vasopressin significantly reduces its affinity for V1a receptors through N-terminal deamination modification and conformational substitution of arginine at position 8. Its binding ability to vascular smooth muscle V1a receptors is only less than one thousandth of that of natural vasopressin, so it almost does not cause vasoconstriction response, greatly weakening the pressor effect and avoiding clinical risks caused by blood pressure fluctuations.

The high specificity of the target enhances safety.

This substance mainly targets the V2 receptors on the surface of kidney and vascular endothelial cells, regulating the release of coagulation related substances through V2 receptors and exerting coagulation regulatory effects; On the other hand, it promotes water reabsorption through the renal V2 receptor, but its scope of action is highly limited to the target receptor and does not cause significant interference with other physiological systems. Natural vasopressin not only acts on V2 receptors, but also on various receptors such as V1a and V1b, causing various non-specific physiological reactions, such as uterine contractions and gastrointestinal motility abnormalities, which increase the risk of adverse reactions. In contrast, the specificity of action of acetic acid vasopressin is higher, and the safety of clinical application is more guaranteed.

The incidence of adverse reactions is lower and milder.

Due to its extremely weak pressor effect, desmopressin acetate injection does not cause adverse reactions such as headaches, dizziness, palpitations, etc. caused by elevated blood pressure, which is in sharp contrast to the common cardiovascular system adverse reactions in the application of natural vasopressin. The possible adverse reactions are mostly related to water metabolism regulation, and often occur in cases of excessive drinking water. Standardized drinking water control can effectively avoid them. The overall incidence of adverse reactions is significantly lower than that of natural vasopressin, and the symptoms are milder, which can be relieved without special intervention, further improving the safety and tolerability of its clinical application.